Pig Kidney Transplanted in Patient Functioned 271 Days
A 66-year-old patient received a genetically engineered pig kidney on January 25, 2025, lasting over nine months.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Should animal-to-human organ transplants be used to help address organ shortages?
A 66-year-old patient in the United States successfully received a genetically engineered pig kidney on January 25, 2025, which remained functional for 271 days. The patient later transitioned to a human donor kidney.
Why it matters
This procedure aimed to test the feasibility of xenotransplantation, the process of transplanting organs between different species, to bridge the critical gap between organ demand and supply for patients with end-stage kidney failure.
The graft functioned for 271 days before the patient received a human donor kidney. While anti-HLA antibody levels—proteins the immune system produces to fight foreign threats—did not increase, the pig kidney sustained damage from thrombotic microangiopathy, a condition involving clots in small blood vessels.
The players
USFDA
The federal agency responsible for overseeing the safety and efficacy of medical devices, human drugs, and biological products.
The Lancet
A prominent weekly peer-reviewed medical journal that publishes clinical research and case studies.
The details
The surgery was performed under a USFDA Expanded Access Investigational New Drug application, a regulatory pathway allowing patients with serious conditions to access experimental treatments. Doctors monitored the patient for T-cell mediated rejection, which manifested on day 14, and a secondary bacterial infection that occurred approximately six months post-transplant. Thrombotic microangiopathy, which caused damage to the organ, is a known challenge in xenotransplantation where the recipient's blood system reacts to the foreign vascular lining.
Timeline
Jan 25, 2025: Patient received the genetically engineered pig kidney.
Day 14 post-transplant: Immune T-cells began attacking the kidney.
Approximately six months post-transplant: Patient developed a bacterial infection.
Sept 2026: Case announced in a Lancet research paper.
The Tech Race
This procedure represents an advancement in the clinical validation of xenotransplantation research initiatives. It follows a series of laboratory and clinical milestones aimed at creating reliable alternatives for the thousands of patients suffering from end-stage renal failure annually.
This case currently serves as a highly specialized medical trial rather than a standard clinical option for the general public. While the transplant demonstrates potential, it remains restricted to highly controlled settings until further safety and longevity data are established.
The takeaway
The successful 271-day function of the pig kidney provides a roadmap for managing immune rejection in interspecies transplants. Researchers and clinicians should monitor forthcoming clinical trial data to see if these protocols can be standardized for patients on national transplant waitlists.
Further reading
For more on the current state of artificial and biological organ replacement, explore our Biotech coverage.
Live Poll
Should animal-to-human organ transplants be used to help address organ shortages?
